Physician profile

Bruce E Landon

Internal Medicine · Boston, MA

NPI 1730126780

$12,046.45

in general payments reported to CMS, 2019-2025

2 companies · $12K in 2025

The $12K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$12,000.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
W. L. Gore & Associates, INC. $12,000.00 2025 Gore Excluder Aaa Endoprosthesis
Tepha INC $46.45 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Bruce E Landon

$12,046.45

in general payments reported 2019-2025

Years
2020-2025
Top company
W. L. Gore & Associates, INC.
Context
The $12K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).

https://glasscript.com/doctor/554720/bruce-e-landon

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.